Navigation Links
Utilizing Public Relation Strategies During Pharmaceutical Lifecycle Management for Greatest Impact on Brand and Consumer Base

CHAPEL HILL, N.C., Dec. 12, 2011 /PRNewswire/ -- Public Relations tactics and tools are broad-reaching, affecting millions of consumers when successful. This makes Public Relations a highly leveraged marketing investment, requiring relatively low investment to reach large audiences. More specifically, Public Relations tools can be easily utilized to benefit all phases of the product lifecycle, especially at launch and brand-building years.

However, field research suggests few companies maximize the full potential of PR campaigns throughout the entire product lifecycle – from preparing and launching to growing and extending a brand, according to Best Practices, LLC study, "Using Public Relations to Launch, Grow and Extend Your Brands."

While Public Relations have long been used as a marketing tool by the pharmaceutical and biotechnology industries, its ability to reach consumers has never been greater. This research will help companies take advantage of the many recommendations and actions to better align PR activities and tactics during the different stages of a product's lifecycle.

Public Relations can also help build a bridge from between a first-generation success to a future blockbuster. Field findings revealed that successor product teams generally should commence Public Relations two years prior to the new product's global launch.

Study topics include:

  • Public relations tools and tactics that are most effective at different lifecycle stages
  • The most effective public relations tools and calls-to-action
  • Successful web site resources for consumers
  • Ideal budget ratios and performance measurements
  • Lessons learned and best practices

The full 108-page report contains over 600 benchmark metrics and more than 35 best practices, delivering insights into the most effective Public Relations channels, tactics and calls-to-action for reaching consumers of pharmaceutical products provided by 18 top biopharmaceutical companies.

Specifically, this research document identifies which Public Relations activities most effectively educate and inform consumers at different points in a product's lifecycle. In addition, this study provides leaders with insights into performance measurements for PR campaigns and what web-based resources best engage patients.

To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http:/


Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. For more information about Best Practices, LLC visit our Web site at

SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
2. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
3. nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure
4. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
5. Life Spine® Announces Completion of Surgeries Utilizing OCTAVE™ Posterior Fusion System
6. iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology
7. Dry Eye Therapy Utilizing Cationic Novasorb® Technology Available Soon From OCuSOFT®
8. Ambry Genetics Announces Launch of Their CancerArray™ Product and Services Utilizing aCGH Technology
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
11. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
Post Your Comments:
(Date:11/24/2015)... , Nueva York , ... Biomedical Devices (ABD), fabricante del Avery Breathing Pacemaker ... Anders Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... --> El doctor Jonzon es un fisiólogo ...
(Date:11/24/2015)... 24, 2015 --> ... Biologics Market by Product Type (Bone Graft, Bine Graft Substitute, ... Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography - ... was valued at $1.90 Billion in 2014 and is expected ... 4.4% during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Charitable giving ... charitable donations are made in the last five weeks of the year totalling over ... created in 2012 to connect the nation’s charities with those individuals who want to ...
(Date:11/24/2015)... (PRWEB) , ... November 25, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and global clinical supply ... present at the upcoming Clinical Trial Supply East Asia Conference, to be held ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
Breaking Medicine News(10 mins):